A Phase 3 interventional study of Ranibizumab in Age Related Macular Degeneration and Choroidal Neovascularization, sponsored by Novartis. Completed at 1 site in Switzerland. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-02-18.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 14th largest by enrollment of the 124 interventional ones that give a count, is one of 8 that started in 2006, is one of 31 in phase 3, and was the 10th registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 531 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one is the 7th largest by enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2006, is one of 23 in phase 3, and was the 7th registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A. This study will assess the safety and efficacy of ranibizumab administered on an as-needed dosing regimen in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who participated in this study included those who had completed participation in the study CRFB002A2301 (ANCHOR; NCT00061594), newly diagnosed patients, as well as previously diagnosed patients who had had recent disease progression.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ranibizumab-naïve (Non-ANCHOR) patients received up to 12 intravitreal injections (Month 0 through Month 11). The dose of 0.3 mg ranibizumab was administered monthly for three consecutive months. From Month 3 through Month 11, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab were injected as individually needed based on re-treatment criteria described in the protocol. For patients who had participated in the ANCHOR study, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab was injected if the patient met re-treatment criteria described in the protocol. Ranibizumab was administered no sooner than 14 days after the previous treatment.
Drug: Ranibizumab
Also known as: rhuFab V2
Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye
Percentage of patients with ocular adverse events in the study eye over the one year (12 month) treatment period.
Time frame: Baseline through end of study (12 month treatment period)
Percentage of Patients With Targeted Grade 3 Adverse Events (AEs) in the Study Eye
Grade 3 targeted AEs included: * 4+ ocular inflammation or 2-3+ ocular inflammation failing to decrease to ≤ 1+ within 30 days * ≥ 30 letter decrease in BCVA that developed within 14 days of ranibizumab injection * sustained (\>15 minutes) loss of light perception due to elevated intraocular pressure (IOP) or a \>20 mm Hg change in IOP persisting longer than 14 days * new retinal tear or detachment involving the macula * new vitreous hemorrhage \>2+ severity not resolving within 14 days * new or increase of previous retinal hemorrhage \>1 disc area in size and involving the fovea
Time frame: Baseline through end of study (12 month treatment period)
Mean Change in Best Corrected Visual Acuity (BCVA) of the Study Eye From Baseline to Month 3
BCVA was assessed using best correction determined from protocol refraction. BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters. BCVA is measured by the number of letters a patient could correctly read on an eye chart; hence an increased score indicates improvement in acuity.
Time frame: Baseline and Month 3
Mean Change in Best Corrected Visual Acuity (BCVA) of the Study Eye From Baseline to Month 12
BCVA was assessed using best correction determined from protocol refraction. BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters. BCVA is measured by the number of letters a patient could correctly read on an eye chart; hence an increased score indicates improvement in acuity.
Time frame: Baseline and Month 12
Mean Change in Central Retinal Thickness of the Study Eye From Baseline to Month 3
Central retinal thickness was assessed using optical coherence tomography (OCT). OCT imaging was performed by trained personnel at each site using the Zeiss Stratus OCT™ 3 with version A6.1 (or more recent) software. Analysis of the OCT images was performed by the investigator. A negative number indicates improvement (reduced thickness).
Time frame: Baseline and Month 3
Mean Change in Central Retinal Thickness of the Study Eye From Baseline to Month 12
Central retinal thickness was assessed using optical coherence tomography (OCT). OCT imaging was performed by trained personnel at each site using the Zeiss Stratus OCT™ 3 with version A6.1 (or more recent) software. Analysis of the OCT images was performed by the investigator. A negative number indicates improvement (reduced thickness).
Time frame: Baseline and Month 12
Time to the First Retreatment After Month 2
Time to first re-treatment is calculated as time difference in months starting from Month 2 until the month of first re-treatment. Criteria for re-treatment: * a \>5 letter decrease in BCVA (determined using EDRS charts) based upon the highest visual acuity score from any prior scheduled study visit (Months 0, 1, 2 or 3) * a \>100 µm increase in central retinal thickness (determined using OCT) from the thinnest measurement from any prior scheduled study visit (Months 0, 1, 2 or 3)
Time frame: Month 2 to Month 11
Total Number of Treatments
Total number of treatments administered during the entire treatment period (Month 0 to 11).
Time frame: Baseline (Month 0) to Month 11
The study population consisted of two groups, one group being naïve to ranibizumab ("Non-ANCHOR" patients) and the other group were those patients who previously were treated with ranibizumab in the ANCHOR study (NCT00061594; "ANCHOR" patients).
| Milestone | Ranibizumab Non-ANCHOR | Ranibizumab ANCHOR |
|---|---|---|
| Started | 513 | 18 |
| Completed | 455 | 14 |
| Not completed | 58 | 4 |
| Withdrew: Adverse event | 30 | 1 |
| Withdrew: Lack of efficacy | 4 | 0 |
| Withdrew: Protocol violation | 3 | 0 |
| Withdrew: Withdrawal by subject | 10 | 0 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Administrative problems | 1 | 0 |
| Withdrew: Death | 6 | 0 |
Percentage of patients with ocular adverse events in the study eye over the one year (12 month) treatment period.
| Percentage of Participants | Ranibizumab Non-ANCHOR | Ranibizumab ANCHOR |
|---|---|---|
| Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye | 48.5 | 38.9 |
BCVA was assessed using best correction determined from protocol refraction. BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters. BCVA is measured by the number of letters a patient could correctly read on an eye chart; hence an increased score indicates improvement in acuity.
| Letters on the ETDRS-like testing charts | Ranibizumab Non-ANCHOR | Ranibizumab ANCHOR |
|---|---|---|
| Baseline | 56.2 ± 12.11 | 47.2 ± 22.10 |
| Change to Month 3 | 5.8 ± 11.12 | 1.9 ± 9.26 |
BCVA was assessed using best correction determined from protocol refraction. BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters. BCVA is measured by the number of letters a patient could correctly read on an eye chart; hence an increased score indicates improvement in acuity.
| Letters on the ETDRS-like testing charts | Ranibizumab Non-ANCHOR | Ranibizumab ANCHOR |
|---|---|---|
| Baseline | 56.2 ± 12.11 | 47.2 ± 22.10 |
| Change to Month 12 | 3.6 ± 13.89 | 1.6 ± 8.66 |
Central retinal thickness was assessed using optical coherence tomography (OCT). OCT imaging was performed by trained personnel at each site using the Zeiss Stratus OCT™ 3 with version A6.1 (or more recent) software. Analysis of the OCT images was performed by the investigator. A negative number indicates improvement (reduced thickness).
| Micrometers | Ranibizumab Non-ANCHOR | Ranibizumab ANCHOR |
|---|---|---|
| Baseline | 339.6 ± 109.38 | 214.1 ± 64.92 |
| Change to Month 3 | -101.1 ± 115.69 | 36.3 ± 72.96 |
Central retinal thickness was assessed using optical coherence tomography (OCT). OCT imaging was performed by trained personnel at each site using the Zeiss Stratus OCT™ 3 with version A6.1 (or more recent) software. Analysis of the OCT images was performed by the investigator. A negative number indicates improvement (reduced thickness).
| Micrometers | Ranibizumab Non-ANCHOR | Ranibizumab ANCHOR |
|---|---|---|
| Baseline | 339.6 ± 109.38 | 214.1 ± 64.92 |
| Change to Month 12 | -91.5 ± 115.47 | 39.3 ± 84.61 |
Time to first re-treatment is calculated as time difference in months starting from Month 2 until the month of first re-treatment. Criteria for re-treatment: * a \>5 letter decrease in BCVA (determined using EDRS charts) based upon the highest visual acuity score from any prior scheduled study visit (Months 0, 1, 2 or 3) * a \>100 µm increase in central retinal thickness (determined using OCT) from the thinnest measurement from any prior scheduled study visit (Months 0, 1, 2 or 3)
| Months | Ranibizumab Non-ANCHOR |
|---|---|
| Time to the First Retreatment After Month 2 | 2 (1 to 6) |
Total number of treatments administered during the entire treatment period (Month 0 to 11).
| Treatments | Ranibizumab Non-ANCHOR | Ranibizumab ANCHOR |
|---|---|---|
| Total Number of Treatments | 5.6 ± 2.37 | 1.1 ± 2.29 |
Grade 3 targeted AEs included: * 4+ ocular inflammation or 2-3+ ocular inflammation failing to decrease to ≤ 1+ within 30 days * ≥ 30 letter decrease in BCVA that developed within 14 days of ranibizumab injection * sustained (\>15 minutes) loss of light perception due to elevated intraocular pressure (IOP) or a \>20 mm Hg change in IOP persisting longer than 14 days * new retinal tear or detachment involving the macula * new vitreous hemorrhage \>2+ severity not resolving within 14 days * new or increase of previous retinal hemorrhage \>1 disc area in size and involving the fovea
| Percentage of Participants | Ranibizumab Non-ANCHOR | Ranibizumab ANCHOR |
|---|---|---|
| Percentage of Patients With Targeted Grade 3 Adverse Events (AEs) in the Study Eye | 2.9 | 0.0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab Non-ANCHOR | — | 80/513 (15.6%) | 199/513 (38.8%) |
| Ranibizumab ANCHOR | — | 4/18 (22.2%) | 8/18 (44.4%) |
| Event | Ranibizumab Non-ANCHOR | Ranibizumab ANCHOR |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/513 | 1/18 |
| Acute myocardial infarctionCardiac disorders | 1/513 | 1/18 |
| Atrial fibrillationCardiac disorders | 2/513 | 1/18 |
| FallInjury, poisoning and procedural complications | 0/513 | 1/18 |
| Humerus fractureInjury, poisoning and procedural complications | 0/513 | 1/18 |
| Pelvic fractureInjury, poisoning and procedural complications | 0/513 | 1/18 |
| Extranodal marginal zone B-cell lymphoma (MALT type)Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/513 | 1/18 |
| Cerebrovascular accidentNervous system disorders | 1/513 | 1/18 |
| HypoaesthesiaNervous system disorders | 0/513 | 1/18 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/513 | 1/18 |
| Event | Ranibizumab Non-ANCHOR | Ranibizumab ANCHOR |
|---|---|---|
| Retinal haemorrhage (Study eye)Eye disorders | 35/513 | 5/18 |
| Visual acuity reduced (Study eye)Eye disorders | 94/513 | 1/18 |
| Choroidal neovascularisation (Fellow eye)Eye disorders | 16/513 | 2/18 |
| Choroidal neovascularisation (Study eye)Eye disorders | 8/513 | 2/18 |
| Retinal haemorrhage (Fellow eye)Eye disorders | 12/513 | 2/18 |
| Retinal oedema (Study eye)Eye disorders | 8/513 | 2/18 |
| Intraocular pressure increased (Study eye)Investigations | 36/513 | 0/18 |
| Visual acuity reduced (Fellow eye)Eye disorders | 23/513 | 1/18 |
| HeadacheNervous system disorders | 13/513 | 1/18 |
| Conjunctival haemorrhage (Study eye)Eye disorders | 28/513 | 0/18 |
| Age, Customized(participants) | Ranibizumab Non-ANCHOR | Ranibizumab ANCHOR | Total |
|---|---|---|---|
| < 50 years | 1 | 0 | 1 |
| 50 to < 65 years | 49 | 0 | 49 |
| 65 to < 75 years | 173 | 5 | 178 |
| 75 to < 85 years | 230 | 12 | 242 |
| ≥ 85 years | 60 | 1 | 61 |
| Sex: Female, Male(Participants) | Ranibizumab Non-ANCHOR | Ranibizumab ANCHOR | Total |
|---|---|---|---|
| Female | 294 | 9 | 303 |
| Male | 219 | 9 | 228 |
The record gives a start of Apr 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab